within Pharmacolibrary.Drugs.ATC.L;

model L04AF08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.81,
    Cl             = 0.00021333333333333333,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.111,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.028833333333333332,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.376,
    k12             = 52.7,
    k21             = 52.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AF08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ritlecitinib is an oral, selective kinase inhibitor, primarily targeting Janus kinase 3 (JAK3) and the TEC family of tyrosine kinases. It is approved for the treatment of severe alopecia areata in adults and adolescents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects; typical values after oral administration based on regulatory reports.</p><h4>References</h4><ol><li><p>Liu, J, et al., &amp; Purohit, VS (2023). Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants. <i>British journal of clinical pharmacology</i> 89(7) 2208–2215. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15695&quot;>10.1111/bcp.15695</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36808638/&quot;>https://pubmed.ncbi.nlm.nih.gov/36808638</a></p></li><li><p>Bauman, JN, et al., &amp; Dowty, ME (2024). The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 52(10) 1124–1136. DOI:<a href=&quot;https://doi.org/10.1124/dmd.124.001843&quot;>10.1124/dmd.124.001843</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39111823/&quot;>https://pubmed.ncbi.nlm.nih.gov/39111823</a></p></li><li><p>Nunez, M, et al., &amp; Ondieki, D (2024). Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(11-12) 1023–1036. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2024.2401603&quot;>10.1080/17425255.2024.2401603</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39252171/&quot;>https://pubmed.ncbi.nlm.nih.gov/39252171</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AF08;
